Revenue segments as reported by the company.

Net product sales

Collaboration revenue

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Other operating (income) expense, net

Acquired in-process research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Regeneron reports robust Q4 earnings, eyes strategic launches and collaborations

Regeneron Pharmaceuticals showcased strong financial performance and pipeline advancements in Q4 2022.
The company's focus on safety, efficacy, and strategic imperatives positions it for future growth.
Challenges include competitive positioning, trial data anticipation, and managing uncertainties.
Opportunities in market launches, accelerated approvals, and innovative collaborations drive future potential.

Regeneron excels in Q1 with strong revenue growth and pipeline advancements

Regeneron Pharmaceuticals delivered a strong performance in Q1 2023, driven by revenue growth and pipeline advancements in key therapeutic areas like DUPIXENT and EYLEA.
Despite operational challenges in market positioning and regulatory considerations, the company's strengths in research capabilities and strategic planning present growth opportunities.
With a focus on commercialization efforts, expanding indications, and leveraging genetic insights, Regeneron is poised to capitalize on opportunities for sustained success and innovation.
Navigating challenges in market competition and regulatory uncertainties, Regeneron remains proactive in addressing key issues to maintain its position as a leading biopharmaceutical company.

Regeneron reports strong Q2 earnings, eyes aflibercept launch

Regeneron Pharmaceuticals demonstrated strong financial performance and commercial success in Q2 2023.
While facing regulatory challenges, the company remains optimistic about pipeline advancements and potential launches.
Balancing efficacy and safety in treatments, Regeneron aims to capitalize on growth opportunities and strategic partnerships.
Robust cash position and focus on patient well-being position Regeneron for continued success and market expansion.

Regeneron posts robust Q3 results, eyes innovation and market growth

Regeneron's Q3 performance reflects strong revenue growth, financial stability, and promising market potential for key products like Dupixent and EYLEA HD.
While facing legal challenges and competitive pressures, the company's strategic focus on innovation, R&D, and shareholder value management positions it for long-term success.
With a robust pipeline, unique therapeutic targets, and a solid financial foundation, Regeneron is poised for continued growth, market leadership, and innovation in the biopharmaceutical industry.

Regeneron posts strong Q4 results, eyes growth through innovation

Regeneron Pharmaceuticals delivered a strong performance in Q4 2023, driven by successful product launches and financial results in line with expectations.
The company's focus on innovation, strategic leadership, and capital allocation priorities position them well for future growth and market success.
While facing challenges in market dynamics and competition, Regeneron has opportunities to leverage new product approvals and innovative treatment approaches.
Overall, Regeneron's performance highlights their resilience, strategic vision, and commitment to advancing healthcare through groundbreaking therapies.

Regeneron posts solid Q1 results, faces FDA request challenges

Regeneron Pharmaceuticals delivered strong financial performance in Q1 2024, driven by Dupixent and EYLEA HD.
The company's robust pipeline and focus on innovation position it well for future growth.
Challenges include FDA requests for Dupixent efficacy analyses and market entry hurdles for new products.
Opportunities lie in advancing therapies for COPD, severe food allergies, and expanding cancer treatment options.

Regeneron posts robust Q2 earnings, eyes pipeline expansion opportunities

Regeneron Pharmaceuticals demonstrated strong financial performance and product sales growth in Q2.
While facing regulatory challenges, the company's pipeline and market position remain robust.
Opportunities for expansion and innovation present avenues for future growth.
Overall, Regeneron's Q2 results reflect resilience and strategic focus.

Regeneron Pharmaceuticals reports strong Q3 results and eyes innovative growth

Regeneron's Q3 performance reflects solid revenue and earnings growth driven by key products. While facing regulatory challenges and capital allocation decisions, the company's focus on innovation and strategic investments positions it well for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron will provide the U.S. with 300,000 doses of its newly authorized Covid-19 antibody treatment by early January, CEO Dr. Leonard Schleifer said.

Regeneron will provide 300,000 doses of Covid treatment for U.S. by early January, CEO Schleifer says

The FDA has granted emergency use authorization to the first COVID-19 treatment option that uses a pair of antibodies to neutralize the novel coronavirus.

Regeneron's Coronavirus Treatment Becomes First Antibody Cocktail to Earn Emergency Use Authorization from FDA

Regeneron antibody ‘cocktail' wins emergency-use authorization from FDA

The U.S. Food and Drug Administration has issued emergency use authorization for Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) COVID-19 antibody cocktail. Why It Matters: The two antibodies in the treatment, casirivimab and imdevimab, were shown to reduce COVID-19-related hospital trips within 28 days of treatment, the FDA said.

Regeneron's COVID Treatment Gets Emergency FDA Approval

Biogen

Pfizer

These three stocks are ready to break out.

3 Best Pharma Stocks to Buy Right Now

TARRYTOWN, N.Y., Nov. 21, 2020 /PRNewswire/ -- First treatment of any kind to have prospectively confirmed and statistically significant anti-viral activity against SARS-CoV-2 Authorized for recently diagnosed, mild to moderate COVID-19 in high-risk patients Initial doses of REGEN-COV2...

Regeneron's REGEN-COV2 is First Antibody Cocktail for COVID-19 to Receive FDA Emergency Use Authorization

Activision Blizzard

Dollar General

Nio stock is worth more than Daimler. It sells 1/200th the number of vehicles.

These 3 Companies Currently Provide Much Better Value Than Nio

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Jefferies Virtual London Healthcare Conference (Transcript)

Bristol-Myers

Johnson & Johnson

Sanofi

SPDR S&P Pharmaceuticals ETF

Zoetis

Pharmaceutical stocks help make the world go round. Without them, common ailments would plague our lives.

7 Pharmaceutical Stocks to Buy for 2021 and Beyond 

Gilead Sciences

Eli Lilly

Pfizer's surprisingly strong initial Covid-19 vaccine efficacy data that came out last week probably marks the beginning of the end of the Covid-19 pandemic. While this is very positive for the economy and the broader stock market, what does it mean for companies that sell or are developing.

Eli Lilly, Regeneron, Gilead: What The Vaccine Means For Covid-19 Treatment Stocks

Inovio Pharmaceuticals

These companies are capitalizing on the market's interest in combating the coronavirus.

Better Coronavirus Stock: Inovio Pharmaceuticals or Regeneron?

Regeneron Pharmaceuticals, Inc. (REGN) Managements Presents at Cowen Virtual Presentation Series 2020 IO Next Summit (Transcript)

Polen Capital Management recently released its Q3 2020 Investor Letter, a copy of which you can download here. During the third quarter of 2020, the Polen Focus Growth Composite Portfolio returned 10.15% gross of fees, while the Russell 1000 Growth Index was up 13.22% and the S&P 500 Index was up 8.93%. You should check out Polen Capital's top 5 stock picks for investors to buy right now, which could be the biggest winners of this year.

Why Regeneron Pharmaceuticals (REGN) Stock is a Compelling Investment Case

Alexion Pharma

Amgen

Bayer AG

The best biotech companies to invest in tend to have a commonality: a strong streak of earnings growth. The post These Red-Hot Biotechs Are Leading The Pack And Could Be Actionable appeared first on Investor's Business Daily.

These Red-Hot Biotechs Are Leading The Pack And Could Be Actionable

Regeneron Pharmaceuticals, Inc. (REGN) Management at Credit Suisse 29th Annual Virtual Healthcare Conference

Moderna

The future these companies envisioned is much closer than before, thanks to the accelerated development and funding the coronavirus has brought.

2020 Will Be a Year to Remember for These 3 Healthcare Stocks

Just because a company has a good quarter in the past doesn't mean that their stock prices will continue to rise in the future. That's why our AI models provide an in-depth look at a company's financials and performance so you can make the best decisions for your portfolio.

Regeneron Pharmaceuticals Earns Top Buy Rating For November

Regeneron Pharmaceuticals, Inc. (REGN) CEO Dr. Leonard Schleifer on Q3 2020 Results - Earnings Call Transcript

The shares of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) are up 0.3% at $588.86 at last check, after the company reported third-quarter earnings of $8.36 per share -- significantly higher than Wall Street's estimates of $7.14 per share -- as well as a revenue beat.

REGN Rises on Quarterly Win, Potential COVID-19 Treatment Approval

Regeneron (REGN) beats on both earnings and sales in the third quarter of 2020 on strong performances by Eylea and Dupixent. Shares rise in pre-market trading.

Regeneron's (REGN) Q3 Earnings & Sales Surpass Estimates

The big biotech fired on all cylinders in the period.

Why There's a Lot to Like With Regeneron's Third-Quarter Results

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) reported its third-quarter financial results before the markets opened on Thursday.

Is Regeneron Making the Case to Buy With Q3 Earnings?

  Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) moved higher by 0.5% in pre-market trading after the company reported Q3 results.

Regeneron Pharmaceuticals: Q3 Earnings Insights

Regeneron earnings and sales beat third-quarter views comfortably for the biotech giant. Shares rose slightly early Thursday.

Regeneron Earnings, Sales Beat; Biotech Giant Rises

Regeneron Pharmaceuticals Inc. shares rose 1.6% in premarket trade Thursday, after the drug company blew past estimates for the third quarter and said it has shared data from its Phase 2/3 COVID-19 vaccine candidate trial with regulators. Regeneron said it had net income of $842 million, or $7.39 a share, in the quarter, up from $670 million, or $5.86 a share, in the year-earlier period.

News for Regeneron Pharmaceuticals Stock (REGN)